Last reviewed · How we verify
Chelation
Chelation, marketed by Novartis Pharmaceuticals, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its current marketed status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Chelation |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis (NA)
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours (PHASE1)
- Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (PHASE2)
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (PHASE2)
- Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
- Effect of Different Chelation Protocols on the Healing of Periapical Lesions in Teeth With Chronic Apical Periodontitis (NA)
- Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |